Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!
Antibody-dependent cellular cytotoxicity (ADCC) is a cell-mediated immune defense mechanism. The effector cells of the immune system can actively destroy target cells whose membrane surface antigens have been bound by specific antibodies. ADCC is part of the adaptive immune response due to its dependence on a prior antibody response. It is independent of the immune complement system, which can also destroy the target, but does not require any other cells. Typical ADCC involves the activation of effector cells, which are usually called natural killer (NK) cells that interact with immunoglobulin G (IgG) antibodies. Other cells, such as macrophages, neutrophils and eosinophils can also mediate ADCC.
Both peripheral blood mononuclear cells (PBMC) and isolated natural killer (NK) cells can be used for ADCC analysis. However, in PBMC, NK cells are the mediator of the ADCC process and the main effector cells. In drug development, the ability of NK cells to bind monoclonal antibodies to target tumor cells is considered to be important for the efficacy of therapeutic monoclonal antibodies screened in ADCC analysis.
At Creative Biolabs, we recognize the interest in using pre-screened donor NK cells and integrating them into our ADCC analysis. Our ADCC products provide a convenient and powerful method to measure the efficacy of antibodies in inducing ADCC in vitro, thereby enabling customers to evaluate and rank their monoclonal antibody candidates to kill tumor/cancer cells through NK-mediated cell lysis.
ADCC Reporter-based Technology
Our ADCC product portfolio is based on the reporter gene system and provides a convenient and powerful method to measure the efficacy of antibodies in inducing ADCC in vitro.
This is achieved by combining cleverly engineered effector cells that closely resemble the natural FcγRIIIA signal transduction pathway with homologous target cells with controlled antigen expression (+) or depletion (-). In summary, our unique iCrea™ ADCC product portfolio provides unparalleled sensitivity for each target, and the system is indeed greater than the sum of its parts.
Features of our ADCC analysis service:
Fig.1 ADCC Assay: Measurement of afucosylated anti-CDXX IgG activity on XX target cells.
Fig.2 ADCC Assay: Measurement of afucosylated anti-CDXX IgG activity on XX target cells, compared with its original drug.
Fig.3 ADCC Assay: Measurement of afucosylated anti-CDXX IgG activity on XX target cells, compared with its original drug.
ADCC Product Portfolio
The iCrea™ ADCC product portfolio includes cell lines provided in an "assay-ready" format, which allows quick and convenient workflows and further reduces assay variability, making it useful for antibody screening, characterization, stability and performance studies.
For more detailed information about our FcγRIIIA/ CD16a binding assay services, please feel free to contact us or directly sent us an inquiry.
|Product Name||Cell Type||CAT#|
|ADCC NF-kB-Luc Reporter Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line||AD-P001-C|
|ADCC NFAT Reporter (Luc) Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line||AD-P002-C|
|ADCC NFAT-CD16 Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line||AD-P003-C|
|ADCC Control Target Cell Line (CD19, CD20, PD-L1), Human Raji Cells||Target Cell Line||AD-P004-C|
|ADCC CTLA-4 Target Cell Line, Human Raji Cells||Target Cell Line||AD-P005-C|
|ADCC hPD-1 Target Cell Line, Human Raji Cells||Target Cell Line||AD-P006-C|
|ADCC hPD-L1 Target Cell Line, Human Raji Cells||Target Cell Line||AD-P007-C|
|ADCC hTIGIT Target Cell Line, Human Raji Cells||Target Cell Line||AD-P008-C|
|ADCC hVISTA Target Cell Line, Human Raji Cells||Target Cell Line||AD-P009-C|
|ADCC CD16 (FcɣRIIIa) Effector Cell Line, Human T Lymphocytes||Effector Cell Line||AD-P010-C|
|ADCP FcγRIIa (H variant) /NFAT Reporter Effector Cell Line, Jurkat T Lymphocytes||Effector Cell Line||AD-P011-C|
Creative Biolabs provides luciferase-based ADCC assay. This Jurkat cell based assay is pioneered by Creative Biolabs, and the methodology is very well accepted by the field. See attached ADCC Reporter Assay Protocol for further details.
All products and services are for Research Use Only. Do Not use in humans.
ADCC Assay WT vs AfucoTM Mabs Visit
Antibody Fc Engineering: Towards Better Therapeutics Visit
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.